These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2489392)

  • 21. [Study of blood quinidine levels obtained by the administration of delayed-action quinidine].
    Renais J; Scebat L; Lenègre J
    Arch Mal Coeur Vaiss; 1971 May; 64(5):701-11. PubMed ID: 4998224
    [No Abstract]   [Full Text] [Related]  

  • 22. Relative bioavailability of a standard and a sustained-release quinidine tablet.
    Gibson DL; Smith GH; Koup JR; Stewart DK
    Clin Pharm; 1982; 1(4):366-8. PubMed ID: 7185532
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of chloroquine-resistant falciparum malaria with a combination of quinine, quinidine and cinchonine (LA40221) in adults by oral and intravenous administration.
    Bunnag D; Harinasuta T; Vanijanonta S; Looareesuwan S; Chittamas S; Punnavut W; Berth J; Druilhe P
    Acta Leiden; 1987; 55():139-49. PubMed ID: 3321829
    [No Abstract]   [Full Text] [Related]  

  • 24. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.
    Zinny MA; Taggart WV
    Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Micro-determination of quinine and quinidine in blood serum by the intermediary of a dye combination formed with rose bengal].
    HASSELMANN M
    C R Hebd Seances Acad Sci; 1957 Jun; 244(23):2860-3. PubMed ID: 13437512
    [No Abstract]   [Full Text] [Related]  

  • 26. Quinine impairs quinidine clearance in rat perfused liver.
    Mihaly GW; Scott H; Hyman MK; Morgan DJ; Smallwood RA
    J Pharm Pharmacol; 1993 Mar; 45(3):215-7. PubMed ID: 8097780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation.
    Mansor SM; Ward SA; Edwards G; Hoaksey PE; Breckenridge AM
    J Pharm Pharmacol; 1990 Jun; 42(6):428-32. PubMed ID: 1979624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of food on the comparative bioavailability of a fast- and slow-release dosage form of quinidine gluconate.
    Spénard J; Sirois G; Gagnon MA
    Int J Clin Pharmacol Ther Toxicol; 1983 Jan; 21(1):1-9. PubMed ID: 6832862
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of quinidine Lipettes -- a sustained release preparation.
    Eriksson JE; Hanson A; Hörlin R; Johansson BW; Ohlsson O; Otto U; Syrén G
    Acta Med Scand; 1979; 205(1-2):53-9. PubMed ID: 367087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation.
    Mansor SM; Ward SA; Edwards G; Hoaksey PE; Breckenridge AM
    J Pharm Pharmacol; 1991 Sep; 43(9):650-4. PubMed ID: 1685525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system.
    Hebden JM; Wilson CG; Spiller RC; Gilchrist PJ; Blackshaw E; Frier ME; Perkins AC
    Pharm Res; 1999 Jul; 16(7):1087-92. PubMed ID: 10450935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A new long acting quinidine preparation].
    Heulin A; Delvaux JC; Vacheron A
    Coeur Med Interne; 1975; 14(1):145-6. PubMed ID: 1091404
    [No Abstract]   [Full Text] [Related]  

  • 33. Quinidine dosage, with special reference to an oral loading dose schedule.
    Collste P; Nordlander R
    Br J Clin Pharmacol; 1979 Mar; 7(3):293-7. PubMed ID: 427006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of the diastereoisomers quinine and quinidine in the ovine fetus.
    Czuba MA; Morgan DJ; Ching MS; Mihaly GW; Ghabrial H; Hardy KJ; Smallwood RA
    J Pharm Sci; 1991 May; 80(5):445-8. PubMed ID: 1880724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relationship between quinidine plasma level and clinical effect for a new quinidine retard-formulation (author's transl)].
    Gaul G; Aldor E
    Arzneimittelforschung; 1981; 31(9):1486-8. PubMed ID: 7197961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Kinidin-Duetter and quinidine sulphate in the prevention of atrial fibrillation. A comparison].
    Bjerkelund C; Orning OM
    Nord Med; 1967 Mar; 77(13):405-7. PubMed ID: 6020765
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of a continuous fluid exchange system in the USP basket-stirrer dissolution test assembly. Part 11: Characterization of the dissolution profile of quinidine sustained-release dosage forms.
    Huynh-Ngoc T; Sirois Gérard
    J Pharm Belg; 1977; 32(1):67-75. PubMed ID: 16996
    [No Abstract]   [Full Text] [Related]  

  • 38. Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate administration.
    Rey AM; Gums JG
    DICP; 1991; 25(7-8):745-6. PubMed ID: 1949932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colorimetric assay of quinine and quinidine in raw materials, formulations, and biological fluids.
    Karawya MS; Diab AM
    J Pharm Sci; 1977 Sep; 66(9):1317-9. PubMed ID: 903873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The effect of ion pair formation on the pharmacokinetics of drugs. 2. The effect of hexylsalicylic acid on the pharmacokinetics of quinine].
    Neubert R; Fürst W; Schulze P; Loh HJ; Jirka M; Wenzel U
    Pharmazie; 1987 Jun; 42(6):393-4. PubMed ID: 3671459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.